{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:48:40Z","timestamp":1788274120334,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T00:00:00Z","timestamp":1601164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.imlet.2020.08.002","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T11:24:12Z","timestamp":1597317852000},"page":"81-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Long-term omalizumab efficacy in allergic rhinitis"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0378-8935","authenticated-orcid":false,"given":"Carlo","family":"Cavaliere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-2822","authenticated-orcid":false,"given":"Elona","family":"Begvarfaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristoforo","family":"Incorvaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sposato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Brunori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ciofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"de Vincentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Masieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.imlet.2020.08.002_bib0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2222.2011.03891.x","article-title":"Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America","volume":"42","author":"Katelaris","year":"2012","journal-title":"Clin. Exp. Allergy"},{"issue":"4","key":"10.1016\/j.imlet.2020.08.002_bib0010","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines - 2016 revision","volume":"140","author":"Bro\u017cek","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.imlet.2020.08.002_bib0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jaci.2012.07.053","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs","volume":"130","author":"Bousquet","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.imlet.2020.08.002_bib0020","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.12659\/MSM.891206","article-title":"A survey of clinical features of allergic rhinitis in adults","volume":"20","author":"Frati","year":"2014","journal-title":"Med. Sci. Monit."},{"issue":"4","key":"10.1016\/j.imlet.2020.08.002_bib0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4193\/Rhino15.400","article-title":"European symposium on precision medicine in allergy and airways diseases: report of the European Union parliament symposium (October 14, 2015)","volume":"53","author":"Muraro","year":"2015","journal-title":"Rhinology."},{"issue":"1","key":"10.1016\/j.imlet.2020.08.002_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/all.12040","article-title":"Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today?","volume":"68","author":"Hellings","year":"2013","journal-title":"Allergy."},{"key":"10.1016\/j.imlet.2020.08.002_bib0035","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2147\/DDDT.S130743","article-title":"Targeted therapy in severe asthma today: focus on immunoglobulin E","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.imlet.2020.08.002_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2014.03.010","article-title":"Omalizumab in asthma: an update on recent developments","volume":"2","author":"Humbert","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.imlet.2020.08.002_bib0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1389450116666141219122157","article-title":"Anti-IgE therapy with Omalizumab for severe asthma: current concepts and potential developments","volume":"16","author":"Pelaia","year":"2015","journal-title":"Curr. Drug Targets"},{"issue":"2","key":"10.1016\/j.imlet.2020.08.002_bib0050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1945892419884774","article-title":"Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Yu","year":"2020","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.imlet.2020.08.002_bib0055","unstructured":"Gazzetta Ufficiale della Repubblica Italiana. Regime di rimborsabilita\u2019 e prezzo di vendita della specialita\u2019 medicinale \u00abXolair\u00bb (omalizumab), autorizzata con procedura centralizzata europea dalla Commissione europea. (Determinazione\/C n. 108\/2006) 2006, November, 30 [Available from: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2006\/11\/30\/06A10894\/sg. Last access May, 25, 2020]."},{"key":"10.1016\/j.imlet.2020.08.002_bib0060","series-title":"Global Strategy for Asthma Management and Prevention 2014","author":"Global Initiative for Asthma","year":"2014"},{"issue":"3","key":"10.1016\/j.imlet.2020.08.002_bib0065","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jaci.2010.06.047","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision","volume":"126","author":"Brozek","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.imlet.2020.08.002_bib0070","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1398-9995.2006.01276.x","article-title":"Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines","volume":"62","author":"Bousquet","year":"2007","journal-title":"Allergy."},{"issue":"5","key":"10.1016\/j.imlet.2020.08.002_bib0075","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1378\/chest.07-1712","article-title":"The use of fraction of exhaled nitric oxide in pulmonary practice","volume":"133","author":"Lim","year":"2008","journal-title":"Chest."},{"issue":"3","key":"10.1016\/j.imlet.2020.08.002_bib0080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaci.2006.01.011","article-title":"Asthma Control Test: reliabiliy, validity, and responsiveness in patients not previously followed by asthma specialists","volume":"117","author":"Schatz","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.imlet.2020.08.002_bib0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.rmed.2017.07.013","article-title":"Long-term \u201creal-life\u201d safety of Omalizumab in patients with severe uncontrolled asthma: a nine-year study","volume":"130","author":"Di Bona","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.imlet.2020.08.002_bib0090","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619841350","article-title":"Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review","volume":"13","author":"Colombo","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"8","key":"10.1016\/j.imlet.2020.08.002_bib0095","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.rmed.2013.04.017","article-title":"The eXpeRience registry: the\u2019 real-world\u2019 effectiveness of Omalizumab in allergic asthma","volume":"107","author":"Braunstahl","year":"2013","journal-title":"Respir. Med."},{"issue":"6","key":"10.1016\/j.imlet.2020.08.002_bib0100","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.anai.2015.04.010","article-title":"Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma","volume":"114","author":"Janson","year":"2015","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2020.08.002_bib0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaip.2012.08.006","article-title":"Association between consistent omalizumab treatment and asthma control","volume":"1","author":"Lafeuille","year":"2013","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.imlet.2020.08.002_bib0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pupt.2015.01.006","article-title":"Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address","volume":"31","author":"Caminati","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.imlet.2020.08.002_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100103","article-title":"Adherence to Omalizumab: a multicenter \u201creal-world\u201d study","volume":"13","author":"Campisi","year":"2020","journal-title":"World Allergy Organ. J."},{"issue":"1","key":"10.1016\/j.imlet.2020.08.002_bib0120","first-page":"45","article-title":"Most common, real life factors affecting effectiveness of omalizumab asthma treatment: a 10-year study","volume":"16","author":"Nurkic","year":"2019","journal-title":"Med. Glas. Zenica. (Zenica)"},{"issue":"2","key":"10.1016\/j.imlet.2020.08.002_bib0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2500\/aap.2009.30.3190","article-title":"Adherence and persistence with omalizumab and fluticasone\/salmeterol within a managed care population","volume":"30","author":"Broder","year":"2009","journal-title":"Allergy Asthma Proc."},{"issue":"2","key":"10.1016\/j.imlet.2020.08.002_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.07.011","article-title":"Omalizumab treatment patterns among patients with asthma in the US medicare population","volume":"8","author":"Li","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.imlet.2020.08.002_bib0135","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness","volume":"12","author":"Pelaia","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"7","key":"10.1016\/j.imlet.2020.08.002_bib0140","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with Omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy."},{"key":"10.1016\/j.imlet.2020.08.002_bib0145","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pupt.2014.09.007","article-title":"Asthma control in severe asthmatics under treatment with Omalizumab: a cross-sectional observational study in Italy","volume":"31","author":"Novelli","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.imlet.2020.08.002_bib0150","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of Omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.imlet.2020.08.002_bib0155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/JAA.S107982","article-title":"Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history","volume":"11","author":"Tabatabaian","year":"2018","journal-title":"J. Asthma Allergy"},{"issue":"24","key":"10.1016\/j.imlet.2020.08.002_bib0160","first-page":"5249","article-title":"Effects of omalizumab therapy on allergic rhinitis: a pilot study","volume":"20","author":"Masieri","year":"2016","journal-title":"Riv. Eur. Sci. Med. Farmacol."},{"issue":"12","key":"10.1016\/j.imlet.2020.08.002_bib0165","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/eji.201847668","article-title":"Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from Fc\u03b5RI","volume":"48","author":"Maggi","year":"2018","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2020.08.002_bib0170","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of Omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.imlet.2020.08.002_bib0175","first-page":"141","article-title":"Omalizumab: efficacy in allergic disease","volume":"46","author":"Spector","year":"2004","journal-title":"Panminerva Med."},{"issue":"6","key":"10.1016\/j.imlet.2020.08.002_bib0180","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1067\/mai.2002.124657","article-title":"Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit","volume":"109","author":"Horak","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.imlet.2020.08.002_bib0185","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.otohns.2008.03.027","article-title":"Relationship between rhinitis duration and worsening of nasal function","volume":"138","author":"Ciprandi","year":"2008","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"1 Pt A","key":"10.1016\/j.imlet.2020.08.002_bib0190","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.imlet.2014.08.010","article-title":"Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients","volume":"162","author":"Mauri","year":"2014","journal-title":"Immunol. Lett."},{"issue":"1","key":"10.1016\/j.imlet.2020.08.002_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2020.08.002_bib0200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18176\/jiaci.0391","article-title":"Effectiveness of omalizumab in severe allergic asthma and nasal polyposis: a real-life study","volume":"30","author":"Tiotiu","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2020.08.002_bib0205","first-page":"167","article-title":"Omalizumab a new prospective: a nasal polyposis","volume":"32","author":"Cavaliere","year":"2018","journal-title":"J. Biol. Regul. Homeost. Agents"},{"issue":"3","key":"10.1016\/j.imlet.2020.08.002_bib0210","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2020.08.002_bib0215","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4193\/Rhin17.139","article-title":"Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study","volume":"56","author":"Bidder","year":"2018","journal-title":"Rhinology."},{"key":"10.1016\/j.imlet.2020.08.002_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","author":"Gevaert","year":"2020","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247820303655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247820303655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:39:07Z","timestamp":1759045147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247820303655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":44,"alternative-id":["S0165247820303655"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2020.08.002","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term omalizumab efficacy in allergic rhinitis","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2020.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}]}}